356 institutions hold shares in Takeda Pharmaceutical Company Limited (TAK), with institutional investors hold 3.52% of the company’s shares. The shares outstanding are 3.15B, and float is at 3.13B with Short Float at 0.27%. Institutions hold 3.52% of the Float.
The top institutional shareholder in the company is Glenview Capital Management, LLC with over 15.26 million shares valued at $277.74 million. The investor’s holdings represent 0.48% of the TAK Shares outstanding. As of Dec 30, 2020, the second largest holder is Paulson & Company, Inc. with 11.3 million shares valued at $205.58 million to account for 0.36% of the shares outstanding. The other top investors are ARK Investment Management, LLC which holds 8.62 million shares representing 0.27% and valued at over $156.85 million, while Adelphi Capital LLP holds 0.24% of the shares totaling 7.58 million with a market value of $138.05 million.
Takeda Pharmaceutical Company Limited (NYSE: TAK) is 0.00% lower on its value in year-to-date trading and has touched a low of $14.46 and a high of $20.00 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The TAK stock was last observed hovering at around $18.64 in the last trading session, with the day’s loss setting it -0.44% off its average median price target of $22.66 for the next 12 months. It is also 41.7% off the consensus price target high of $31.22 offered by 14 analysts, but current levels are 3.7% higher than the price target low of $18.90 for the same period.
Currently trading at $18.20, the stock is -3.36% and 0.97% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.34 million and changing -2.36% at the moment leaves the stock 1.41% off its SMA200. TAK registered 23.56% gain for a year compared to 6-month loss of 3.12%. The firm has a 50-day simple moving average (SMA 50) of $18.23 and a 200-day simple moving average (SMA200) of $17.82.
The stock witnessed a 4.36% gain in the last 1 month and extending the period to 3 months gives it a 0.00%, and is -5.11% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.48% over the week and 1.52% over the month.
Takeda Pharmaceutical Company Limited (TAK) has around 47495 employees, a market worth around $57.38B and $29.12B in sales. Current P/E ratio is 34.83 and Fwd P/E is 17.33. Distance from 52-week low is 25.86% and -9.00% from its 52-week high.
Takeda Pharmaceutical Company Limited (TAK) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Takeda Pharmaceutical Company Limited (TAK) is a “Overweight”. 14 analysts offering their recommendations for the stock have an average rating of 2.00, where 3 rate it as a Hold and 2 think it is a “Overweight”. 9 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Takeda Pharmaceutical Company Limited is expected to release its quarterly report on 08/05/2021 and quarterly earnings per share for the current quarter are estimated at $0 with sales reaching $7.49M over the same period.The EPS is expected to grow by 530.80% this year, but quarterly earnings will post -4.30% year-over-year. Quarterly sales are estimated to shrink -99.10% in year-over-year returns.
Takeda Pharmaceutical Company Limited (TAK): Who are the competitors?
The company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading 22.74% up over the past 12 months and Sanofi (SNY) that is 15.33% higher over the same period. Pfizer Inc. (PFE) is 16.47% up on the 1-year trading charts. Short interest in the company’s stock has risen 30.17% from the last report on Feb 11, 2021 to stand at a total of 5.88 million short shares sold with a short interest ratio of 2.27.